Adynxx (FRA:HL1C) Short-Term Debt : €7.94 Mil (As of Sep. 2019)

View and export this data going back to 1998. Start your Free Trial

What is Adynxx Short-Term Debt?

Adynxx's Short-Term Debt for the quarter that ended in Sep. 2019 was €7.94 Mil.

Adynxx's quarterly Short-Term Debt increased from Mar. 2019 (€0.00 Mil) to Jun. 2019 (€6.98 Mil) and increased from Jun. 2019 (€6.98 Mil) to Sep. 2019 (€7.94 Mil).

Adynxx's annual Short-Term Debt declined from Dec. 2016 (€10.94 Mil) to Dec. 2017 (€0.00 Mil) but then stayed the same from Dec. 2017 (€0.00 Mil) to Dec. 2018 (€0.00 Mil).

Adynxx Short-Term Debt Historical Data

The historical data trend for Adynxx's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Short-Term Debt Chart

Adynxx Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Short-Term Debt

Get a 7-Day Free Trial

10.94

Adynxx Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	6.98	7.94

Adynxx Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Adynxx Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Adynxx's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Adynxx (FRA:HL1C) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (FRA:HL1C) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

100 Pine Street, Suite 500, San Francisco, CA, USA, 94111

Website

http://www.adynxx.com

Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.

Adynxx (FRA:HL1C) Headlines

No Headlines